title: Bronchodilator response to inhaled beta-2 agonist and anticholinergic drugs in patients with bronchiectasis.
abstract: OBJECTIVE
  An increase in incidence of reversible airflow obstruction and bronchial hyperresponsiveness occurs in patients with bronchiectasis. We conducted a study to assess the efficacy of bronchodilators in the treatment of bronchiectasis.
  
  
  METHODS
  Twenty-four patients with confirmed bronchiectasis were studied. Each patient inhaled fenoterol 400 microg administered by metered dose inhaler via a spacer after a baseline lung function and a lung function test was repeated 30 min later. This was followed by a second dose of fenoterol 5 mg via nebulizer and another lung function test 30 min later. A repeat study was done at least 24 h later with ipratropium bromide 40 microg by metered dose inhaler and 500 microg by a nebulizer.
  
  
  RESULTS
  The results showed a significant improvement from baselines (mean percentage change +/- SD) of peak expiratory flow rate (PEF) by 8.5 +/- 8.72% and 15.3 +/- 11.63%, forced expiratory volume in 1 s (FEV1) by 8.77 +/- 9.69% and 10.2 +/- 12.2% and forced vital capacity (FVC) by 10.25 +/- 11.61% and 10.09 +/- 10.88% after low- and high-dose fenoterol, respectively. The improvements after low- and high-dose ipratropium bromide for PEE FEV1 and FVC were 9.89 +/- 9.35% and 14.39 +/- 12.82%, 9.38 +/- 10.41% and 13.52 +/- 17.09%, and 8.03 +/- 10.85% and 9.63 +/- 13.85%, respectively. Eleven patients (45.8%) responded to one or both bronchodilators significantly (> 15% improvement in FEV1). Five patients (20%) responded to both, three (12%) to fenoterol alone and another three (12%) to ipratropium bromide alone.
  
  
  CONCLUSIONS
  There is significant bronchodilator response in a subset of patients with bronchiectasis and patients with bronchiectasis should therefore undergo bronchodilator testing. Skin prick testing against a panel of nine allergens done on each individual yielded a positive result in 13 patients (54.2%).
authors.affiliation: Department of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur. jeffrey@hukm.ukm.my
authors.forename: J A
authors.initials: JA
authors.lastname: Hassan
authors.forename: S
authors.initials: S
authors.lastname: Saadiah
authors.forename: H
authors.initials: H
authors.lastname: Roslan
authors.forename: B M
authors.initials: BM
authors.lastname: Zainudin
mesh_terms: D000280:Administration, Inhalation; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage*; D000328:Adult; D000368:Aged; D001987:Bronchiectasis / Q000175:diagnosis / Q000188:drug therapy*; D001993:Bronchodilator Agents; D018680:Cholinergic Antagonists / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005280:Fenoterol / Q000008:administration & dosage*; D006801:Humans; D009241:Ipratropium; D008296:Malaysia; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012129:Respiratory Function Tests; D016896:Treatment Outcome
chemical_list: D000318:Adrenergic beta-Agonists; D001993:Bronchodilator Agents; D018680:Cholinergic Antagonists; D005280:Fenoterol; D009241:Ipratropium